36 results on '"Boyapati A"'
Search Results
2. Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection
3. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
4. MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
5. Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases
6. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases
7. Genome-Wide Cell-Free DNA Fragmentation Analyses for Early, Non-Invasive Detection of Treatment Response to Standard of Care Adjuvant Radiation Treatment in High-Grade Gliomas
8. 10. Outcomes of 3-level cervical disc arthroplasty comparing with 3-level anterior cervical discectomy and fusion
9. Ability of Chitosan Gels to Disrupt Bacterial Biofilms and Their Applications in the Treatment of Bacterial Vaginosis
10. Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
11. P-052 LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
12. P-044 Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1
13. P-005 Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)
14. t(8;21)(q22;q22) fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression
15. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts
16. Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO
17. Su1731 VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE OF REMISSION IN CROHN'S DISEASE: A COCHRANE SYSTEMATIC REVIEW
18. 36. Mechanisms via Which Traumatic Stress Leads to Persistent Fear in Male and Female Rats
19. Dysrangements of TLR-2 in Ph(-) myeloproliferativeneoplasm Related to Jak2 Mutations and Leukocytosis
20. Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
21. Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma
22. OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multiple myeloma
23. Wadsworth–Emmons reaction: the unique catalytic reaction by a solid base
24. SV40 17KT antigen complements dnaj mutations in large T antigen to restore transformation of primary human fibroblasts
25. Critical Role for SV40 Small-t Antigen in Human Cell Transformation
26. Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
27. Poster: MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
28. Tu1767 - MDR1-Deficiency Unmasks Mitochondrial Dysfunction as a Pathogenic Mechanism in IBD
29. 374 - Mitochondrial DNA is a Damage-Associated Molecular Pattern (DAMP) Released during Active IBD Promoting TLR9-Mediated Inflammation
30. Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?
31. Disruption of the NHR4 Domain Structure in AML1-ETO Abrogates Its Interaction with SON and Promotes AML1-ETO-Associated Leukemogenesis.
32. A t(8;21) Fusion Protein Disrupts the Spindle Checkpoint and Promotes Aneuploidy.
33. AML1-ETO9a, an Alternatively Spliced Form of AML1-ETO, Collaborates with AML1-ETO To Promote Leukemogenesis.
34. The Dimerization Domain and C-Terminal NCoR/SMRT Interacting Zinc-Finger Domain of t(8;21) Fusion Protein AML1-ETO Have Critical and Opposite Effects on Leukemogenesis.
35. Differential Effects on Cell Cycle Regulators by AML1-ETO and a C-Terminal Truncated AML1-ETO (From Tumor Suppressor to Oncogene).
36. Identification of a Novel Alternatively Spliced Form of AML1-ETO and Analysis of Its Role in Leukemogenesis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.